Hybio Pharmaceutical Co., Ltd. (300199.SZ)
CNY 13.0
(4.17%)
CNY 13.0
(4.17%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 431.38 Million CNY | -38.75% |
| 2022 | 704.32 Million CNY | -4.3% |
| 2021 | 735.97 Million CNY | 1.97% |
| 2020 | 721.72 Million CNY | 17.51% |
| 2019 | 614.19 Million CNY | -51.43% |
| 2018 | 1.26 Billion CNY | 1.46% |
| 2017 | 1.24 Billion CNY | 45.75% |
| 2016 | 855.04 Million CNY | 11.3% |
| 2015 | 768.26 Million CNY | 83.17% |
| 2014 | 419.42 Million CNY | 39.16% |
| 2013 | 301.4 Million CNY | 33.37% |
| 2012 | 225.99 Million CNY | 36.4% |
| 2011 | 165.68 Million CNY | 35.88% |
| 2010 | 121.92 Million CNY | 31.51% |
| 2009 | 92.71 Million CNY | 19.85% |
| 2008 | 77.35 Million CNY | 37.65% |
| 2007 | 56.2 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 148.8 Million CNY | 398.88% |
| 2024 Q2 | 102.37 Million CNY | -31.2% |
| 2024 Q3 | 119.5 Million CNY | 16.73% |
| 2023 Q3 | 76.27 Million CNY | -48.83% |
| 2023 FY | 431.38 Million CNY | -38.75% |
| 2023 Q2 | 149.05 Million CNY | -15.42% |
| 2023 Q4 | 29.82 Million CNY | -60.89% |
| 2023 Q1 | 176.22 Million CNY | 1.65% |
| 2022 Q1 | 167.21 Million CNY | -26.74% |
| 2022 Q4 | 173.35 Million CNY | -0.62% |
| 2022 Q3 | 174.43 Million CNY | -7.86% |
| 2022 FY | 704.32 Million CNY | -4.3% |
| 2022 Q2 | 189.31 Million CNY | 13.22% |
| 2021 Q3 | 141.55 Million CNY | -24.55% |
| 2021 Q1 | 178.57 Million CNY | 421.47% |
| 2021 Q2 | 187.6 Million CNY | 5.06% |
| 2021 Q4 | 228.24 Million CNY | 61.24% |
| 2021 FY | 735.97 Million CNY | 1.97% |
| 2020 FY | 721.72 Million CNY | 17.51% |
| 2020 Q4 | 34.24 Million CNY | -86.15% |
| 2020 Q3 | 247.33 Million CNY | -0.4% |
| 2020 Q2 | 248.32 Million CNY | 29.46% |
| 2020 Q1 | 191.82 Million CNY | 234.11% |
| 2019 Q4 | 57.41 Million CNY | -45.87% |
| 2019 FY | 614.19 Million CNY | -51.43% |
| 2019 Q1 | 192.83 Million CNY | -46.35% |
| 2019 Q2 | 257.87 Million CNY | 33.73% |
| 2019 Q3 | 106.06 Million CNY | -58.87% |
| 2018 Q2 | 378.22 Million CNY | 40.79% |
| 2018 Q1 | 268.64 Million CNY | -49.48% |
| 2018 FY | 1.26 Billion CNY | 1.46% |
| 2018 Q4 | 359.4 Million CNY | 39.22% |
| 2018 Q3 | 258.16 Million CNY | -31.74% |
| 2017 Q3 | 235.49 Million CNY | -13.72% |
| 2017 FY | 1.24 Billion CNY | 45.75% |
| 2017 Q2 | 272.93 Million CNY | 32.48% |
| 2017 Q1 | 206.02 Million CNY | -14.25% |
| 2017 Q4 | 531.77 Million CNY | 125.82% |
| 2016 Q3 | 271.25 Million CNY | 54.09% |
| 2016 FY | 855.04 Million CNY | 11.3% |
| 2016 Q2 | 176.03 Million CNY | 5.1% |
| 2016 Q1 | 167.48 Million CNY | -46.1% |
| 2016 Q4 | 240.27 Million CNY | -11.42% |
| 2015 Q3 | 192.1 Million CNY | 34.99% |
| 2015 Q4 | 310.73 Million CNY | 61.75% |
| 2015 Q1 | 123.1 Million CNY | -8.49% |
| 2015 Q2 | 142.31 Million CNY | 15.61% |
| 2015 FY | 768.26 Million CNY | 83.17% |
| 2014 Q3 | 127.51 Million CNY | 42.6% |
| 2014 Q4 | 134.52 Million CNY | 5.49% |
| 2014 Q2 | 89.42 Million CNY | 31.58% |
| 2014 Q1 | 67.96 Million CNY | -40.71% |
| 2014 FY | 419.42 Million CNY | 39.16% |
| 2013 Q3 | 70.23 Million CNY | 2.53% |
| 2013 Q1 | 48.04 Million CNY | -35.78% |
| 2013 Q2 | 68.5 Million CNY | 42.59% |
| 2013 Q4 | 114.62 Million CNY | 63.21% |
| 2013 FY | 301.4 Million CNY | 33.37% |
| 2012 Q4 | 74.8 Million CNY | 32.87% |
| 2012 Q1 | 40.28 Million CNY | -25.05% |
| 2012 FY | 225.99 Million CNY | 36.4% |
| 2012 Q2 | 54.6 Million CNY | 35.55% |
| 2012 Q3 | 56.29 Million CNY | 3.09% |
| 2011 Q1 | 33.11 Million CNY | -20.01% |
| 2011 Q2 | 39.31 Million CNY | 18.73% |
| 2011 Q3 | 39.49 Million CNY | 0.44% |
| 2011 Q4 | 53.75 Million CNY | 36.11% |
| 2011 FY | 165.68 Million CNY | 35.88% |
| 2010 FY | 121.92 Million CNY | 31.51% |
| 2010 Q1 | 16.24 Million CNY | 0.0% |
| 2010 Q3 | 28.6 Million CNY | -19.81% |
| 2010 Q2 | 35.67 Million CNY | 119.58% |
| 2010 Q4 | 41.4 Million CNY | 44.73% |
| 2009 FY | 92.71 Million CNY | 19.85% |
| 2008 FY | 77.35 Million CNY | 37.65% |
| 2007 FY | 56.2 Million CNY | 0.0% |